Skip to main content
Clinical Trials/DRKS00013491
DRKS00013491
Completed
Phase 3

ACURATE TF Transfemoral Aortic Bioprosthesis for Implantation in patients with severe aortic stenosis - ACURATE TF 2013-01

Symetis SA0 sites39 target enrollmentFebruary 9, 2018

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
I35.0
Sponsor
Symetis SA
Enrollment
39
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 9, 2018
End Date
March 19, 2019
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Symetis SA

Eligibility Criteria

Inclusion Criteria

  • 1\. Patient 75 years of age and older
  • 2\. Severe aortic stenosis defined as:
  • o Mean aortic gradient \> 40 mmHg or
  • o Peak jet velocity \> 4\.0 m/s or
  • o Aortic valve area of \< 1\.0 cm2
  • 3\. High risk candidate for conventional AVR defined as:
  • o Logistic EuroSCORE 1 \= 20 or
  • o Heart team (cardiologist and cardiac surgeon) consensus that patient is not a surgical candidate for conventional AVR due to significant co\-morbid conditions unrelated to aortic stenosis
  • 4\. NYHA Functional Class \> II
  • 5\. Aortic annulus diameter from \= 21mm up to \= 27mm by CT or TEE

Exclusion Criteria

  • 1\. Unicuspid or bicuspid aortic valve
  • 2\. Extreme eccentricity of calcification
  • 3\. Severe mitral regurgitation (\>2\+)
  • 4\. Pre\-existing prosthetic heart valve in any position and / or prosthetic ring
  • 5\. Aortic or peripheral anatomy NOT appropriate for transfemoral implant
  • 6\. Thoracic (TAA) or abdominal (AAA) aortic aneurysm
  • 7\. Presence of endovascular stent graft for treatment of TAA or AAA
  • 8\. Trans\-esophageal echocardiogram (TEE) is contraindicated
  • 9\. ECHO evidence of intracardiac mass, thrombus, or vegetation
  • 10\. LVEF \< 30% by ECHO

Outcomes

Primary Outcomes

Not specified

Similar Trials